Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
about
The role of fibrosis in Duchenne muscular dystrophyTransient compartment-like syndrome and normokalaemic periodic paralysis due to a Ca(v)1.1 mutation.23Na MRI and myometry to compare eplerenone vs. glucocorticoid treatment in Duchenne dystrophy.Eplerenone repolarizes muscle membrane through Na,K-ATPase activation by Tyr10 dephosphorylation.Quantitative assessment of muscle injury by (23)Na magnetic resonance imaging.Tissue-resident Sca1+ PDGFRα+ mesenchymal progenitors are the cellular source of fibrofatty infiltration in arrhythmogenic cardiomyopathy.
P2860
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@ast
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@en
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@nl
type
label
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@ast
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@en
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@nl
prefLabel
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@ast
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@en
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@nl
P2093
P2860
P1433
P1476
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
@en
P2093
Frank Lehmann-Horn
Hans-Michael Meinck
Johannes Scharrer
Karin Jurkat-Rott
Marc-André Weber
Simon Breitenbach
P2860
P577
2012-05-01T00:00:00Z